P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood-brain barrier in mice after a 10-day administration of amitriptyline

Journal of Psychopharmacology

Volumn 18, Issue 1, 2004, Pages 66-74

  Grauer, Markus T ^a   Uhr, Manfred ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

ABCB1; Amitriptyline; Brain; Knockout mice; MDR1; Multi drug resistance; Nortriptyline; P glycoprotein

Indexed keywords

10 HYDROXYAMITRIPTYLINE; AMITRIPTYLINE; DRUG METABOLITE; GLYCOPROTEIN P; NORTRIPTYLINE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG MUSCLE LEVEL; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; KNOCKOUT MOUSE; LUNG; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPLEEN; TESTIS;

AMITRIPTYLINE; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BLOOD-BRAIN BARRIER; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, KNOCKOUT; NORTRIPTYLINE; P-GLYCOPROTEIN; TISSUE DISTRIBUTION;

EID: 2442513407     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881104042831     Document Type: Article

References (30)

1. Barbui C, Hotopf M (2001) Amitriptyline versus the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 178: 129-144
2. Cordon-Cardo C, O'Brien J P, Boccia J, Casals D, Bertino J R, Melamed M R (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287
3. Coudore F, Fialip J, Eschalier A, Lavarenne J (1994) Mice plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after half-life repeated administration. Comparison with acute administration. Fundam Clin Pharmacol 8: 525-531
4. Coudore F, Besson A, Eschalier A, Lavarenne J, Fialip J (1996) Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after one and six half-life repeated administrations to rats. Gen Pharmacol 27: 215-219
5. Demeule M, Labelle M, Régina A, Berthelet F, Béliveau R (2001) Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P-glycoprotein isoforms. Biochem Biophys Res Commun 281: 827-834
6. Devault A, Gros P (1990) Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 10: 1652-1663
7. Durr D, Stieger B, Kullak-Ublick G A, Rentsch K M, Steinert H C, Meier P J, Fattinger K (2000) St John's Wort induces intestinal P-glcoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68: 598-604
8. Fromm M F (2000) P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38: 69-74
9. Gottesman M M, Hrycyna C A, Schoenlein P V, Germann U A, Pastan I (1995) Genetic analysis of the multidrug transporter. Annu Rev Genet 29: 607-649
10. Hoffmeyer S, Burk O, von Richter O, Arnold H P, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478
11. Johne A, Schmider J, Brockmöller J, Stadelmann A M, Störmer E, Bauer S, Scholler G, Langheinrich M, Roots I (2002) Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St John's wort (Hypericum perforatum). J Clin Psychopharmacol 22: 46-54
12. Karssen A M, Meijer O C, van der Sandt I C, Lucassen P J, de Lange E C, de Boer A G, de Kloet E R (2001) Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142: 2686-2694
13. Karssen A M, Meijer O C, van der Sandt I C, de Boer A G, de Lange E C, de Kloet E R (2002) The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol 175: 251-260
14. Kerb R, Hoffmeyer S, Brinkmann U (2001) ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2: 51-64
15. Meijer O C, de Lange E C, Breimer D D, de Boer A G, Workel J O, de Kloet E R (1998) Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1 A P-glycoprotein knockout mice. Endocrinology 139: 1789-1793
16. Mukhopadhyay T, Batsakis J G, Kuo M T (1988) Expression of the mdr (P-glycoprotein) gene in Chinese hamster digestive tracts. J Natl Cancer Inst 80: 269-275
17. Olesen O V, Linnet K (1997) Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P450 isozymes. Drug Metab Dispos 25: 740-744
18. Österberg T, Norinder U (2001) Prediction of drug transport processes using simple parameters and PLS statistics. The use of ACD/logP and ACD/ChemSketch descriptors. Eur J Pharm Sci 12: 327-337
19. Pariante C M, Makoff A, Lovestone S, Feroli S, Heyden A, Miller A H, Kerwin R W (2001) Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol 134: 1335-1343
20. Preskorn S H, Raichle M E, Hartman B K (1982) Antidepressants alter cerebrovascular permeability and metabolic rate in primates. Science 217: 250-252
21. Roberts R L, Joyce P R, Mulder R T, Begg E, Kennedy M A (2002) A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics 2: 191-196
22. Sarmento A, Albino-Teixeira A, Azevedo I (1990) Amitriptyline-induced morphological alterations of the rat blood-brain barrier. Eur J Pharmacol 176: 69-74
23. Schinkel A H, Smit J J, van Tellingen O, Beijnen J H, Wagenaar E, van Deemter L, Mol C A, van der Valk M A, Robanus-Maandag E C, te Riele H P, Berns A J M, Borst P (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502
24. Schinkel A H, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit J J, van der Valk M A, Voordouw A C, Spits H, van Tellingen O, Zijlmans J M, Fibbe W E, Borst P (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94: 4028-4033
25. Thiebaut F, Tsuruo T, Hamada H, Gottesman M M, Pastan I, Willingham M C (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738
26. Tsuji A, Tamai I (1997) Blood-brain barrier function of P-glycoprotein. Adv Drug Delivery Rev 25: 287-298
27. Uhr M, Steckler T, Yassouridis A, Holsboer F (2000) Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain-barrier deficiency due to Mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22: 380-387
28. Uhr M, Holsboer F, Müller M B (2002) Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 14: 753-759
29. Varga A, Nugel H, Baehr R, Marx U, Hevér A, Nacsa J, Ocsovszky I, Molnar J (1996) Reversal of multidrug resistance by amitriptyline in vitro. Anticancer Res 16: 209-211
30. Wijnholds J, de Lange E C, Scheffer G L, van den Berg D-J, Mol C A, van der Valk M A, Schinkel A H, Scheper R J, Breimer D D, Borst P (2000) Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 105: 279-285